Switch theme
Sign up to access all valuation multiples
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
2003
338
LTM Revenue $60.0M
LTM EBITDA -$190M
-$163M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sutro Biopharma has a last 12-month revenue (LTM) of $60.0M and a last 12-month EBITDA of -$190M.
In the most recent fiscal year, Sutro Biopharma achieved revenue of $62.0M and an EBITDA of -$187M.
Sutro Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sutro Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $60.0M | XXX | $62.0M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$190M | XXX | -$187M | XXX | XXX | XXX |
| EBITDA Margin | -317% | XXX | -301% | XXX | XXX | XXX |
| EBIT | -$185M | XXX | -$238M | XXX | XXX | XXX |
| EBIT Margin | -309% | XXX | -384% | XXX | XXX | XXX |
| Net Profit | -$183M | XXX | -$227M | XXX | XXX | XXX |
| Net Margin | -305% | XXX | -367% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Sutro Biopharma's stock price is $1.
Sutro Biopharma has current market cap of $64.2M, and EV of -$163M.
See Sutro Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$163M | $64.2M | XXX | XXX | XXX | XXX | $-2.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Sutro Biopharma has market cap of $64.2M and EV of -$163M.
Sutro Biopharma's trades at -2.6x EV/Revenue multiple, and 0.9x EV/EBITDA.
Equity research analysts estimate Sutro Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sutro Biopharma has a P/E ratio of -0.3x.
See valuation multiples for Sutro Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $64.2M | XXX | $64.2M | XXX | XXX | XXX |
| EV (current) | -$163M | XXX | -$163M | XXX | XXX | XXX |
| EV/Revenue | -2.7x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/FCF | 1.2x | XXX | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSutro Biopharma's last 12 month revenue growth is -11%
Sutro Biopharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Sutro Biopharma's rule of 40 is -48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sutro Biopharma's rule of X is -344% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sutro Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -11% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -317% | XXX | -301% | XXX | XXX | XXX |
| EBITDA Growth | -38% | XXX | 64% | XXX | XXX | XXX |
| Rule of 40 | -48% | XXX | -312% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -344% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 406% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 484% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sutro Biopharma acquired XXX companies to date.
Last acquisition by Sutro Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Sutro Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sutro Biopharma founded? | Sutro Biopharma was founded in 2003. |
| Where is Sutro Biopharma headquartered? | Sutro Biopharma is headquartered in United States of America. |
| How many employees does Sutro Biopharma have? | As of today, Sutro Biopharma has 338 employees. |
| Who is the CEO of Sutro Biopharma? | Sutro Biopharma's CEO is Ms. Jane Chung, R.Ph.. |
| Is Sutro Biopharma publicy listed? | Yes, Sutro Biopharma is a public company listed on NAS. |
| What is the stock symbol of Sutro Biopharma? | Sutro Biopharma trades under STRO ticker. |
| When did Sutro Biopharma go public? | Sutro Biopharma went public in 2018. |
| Who are competitors of Sutro Biopharma? | Similar companies to Sutro Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sutro Biopharma? | Sutro Biopharma's current market cap is $64.2M |
| What is the current revenue of Sutro Biopharma? | Sutro Biopharma's last 12 months revenue is $60.0M. |
| What is the current revenue growth of Sutro Biopharma? | Sutro Biopharma revenue growth (NTM/LTM) is -11%. |
| What is the current EV/Revenue multiple of Sutro Biopharma? | Current revenue multiple of Sutro Biopharma is -2.7x. |
| Is Sutro Biopharma profitable? | Yes, Sutro Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sutro Biopharma? | Sutro Biopharma's last 12 months EBITDA is -$190M. |
| What is Sutro Biopharma's EBITDA margin? | Sutro Biopharma's last 12 months EBITDA margin is -317%. |
| What is the current EV/EBITDA multiple of Sutro Biopharma? | Current EBITDA multiple of Sutro Biopharma is 0.9x. |
| What is the current FCF of Sutro Biopharma? | Sutro Biopharma's last 12 months FCF is -$140M. |
| What is Sutro Biopharma's FCF margin? | Sutro Biopharma's last 12 months FCF margin is -233%. |
| What is the current EV/FCF multiple of Sutro Biopharma? | Current FCF multiple of Sutro Biopharma is 1.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
